CRISPR Therapeutics AG Dividend History (CRSP)
CRISPR Therapeutics AG does not pay dividends currently 😔
They might in the future, check back soon!
About CRISPR Therapeutics AG
CRISPR Therapeutics AG is a cutting-edge biopharmaceutical company focused on developing transformative gene-based medicines utilizing CRISPR/Cas9 gene-editing technology. Founded in 2013 by Emmanuelle Charpentier and Shaun Foy, the company has its headquarters in Zug, Switzerland, with research and development operations in Cambridge, Massachusetts, USA. The company's innovative approach aims to tackle serious genetic disorders and bring groundbreaking therapies to market. As of the latest updates, Samarth Kulkarni serves as the CEO, steering the company through its ambition to harness the revolutionary potential of CRISPR. CRISPR Therapeutics has garnered attention for its work in developing therapies for diseases such as sickle cell anemia and beta-thalassemia, amongst others. The company's revenue and financial details frequently update with its progress in clinical trials and partnerships, which have included collaborations with organizations like Vertex Pharmaceuticals. CRISPR Therapeutics is at the forefront of genetic medicine, reflecting both the excitement and challenges inherent in pioneering new medical frontiers.
The biotech industry has lagged the broader market in 2024, but CRISPR Therapeutics and Exelixis still look like solid long-term picks. CRISPR Therapeutics has a promising gene-editing therapy, while Exelixis' cancer drug Cabometyx continues to drive strong financial results.
The Motley Fool · Published on Sat Dec 07 2024CRISPR Therapeutics' first gene therapy, Casgevy, has seen a slow launch, leading to a 47% drop in the stock price. However, the company has a strong pipeline and cash position, making it a risky but potentially rewarding investment.
The Motley Fool · Published on Sun Nov 24 2024